associated with cancer treatments, or by parathyroidectomy, commonly lead to hypoparathyroidism. Patients with hypoparathyroidism suffer from serious complications including painful tetany and muscle spasms, chronic kidney problems such as nephrocalcinosis or even renal failure, arrhythmias and signifi cant CNS problems. Therefore, restoration of parathyroid gland function would greatly improve the quality of life of an individual suffering from hypoparathyroidism. The reimplantation of parathyroid glands following thyroid surgery has been somewhat successful for restoring parathyroid function; however, this is not an approach that can always be used and must often be supplemented pharmacologically. The recent generation of hiPS cells has opened the door to the possibility of developing autologous cellular therapies with patient derived cells that could be benefi cial for individuals with hypoparathyroidism. Reprogramming patient-specifi c human somatic cells into iPS cells with pluripotence features similar to those of embryonic stem (ES) cells creates an opportunity for autologous repair and/or regeneration of tissues/ organs that have been damaged by disease or therapeutic interventions with minimal prospect for immune rejection. To achieve this goal, an in vitro culture protocol was developed to generate functional parathyroid gland epithelial cell progenitors from patient specifi c hiPS cells. The protocol was designed based on human embryological developmental stages to enhance the potential for generating a mature functional gland epithelium that will actively secret parathyroid hormone in response to environmental stimuli. This study assesses the directed differentiation of hiPS cells into defi nitive endoderm, anterior foregut endoderm (AFE), and parathyroid progenitor cells. The experiments demonstrate that brief treatment of the cells with high doses of Activin A in the early stages of iPS cell differentiation promotes endodermal differentiation, and that the readdition of high doses of Activin A to a parathyroid differentiation cocktail that includes Sonic HedgeHog (SHH) after the detection of pharyngeal pouches, leads to the increased expression of parathyroid markers. This work has been supported by Pennsylvania Cystic Fibrosis, Inc and the Hearing Research Institute.
iPSC-Derived Cardiomyocytes from the Urine of a Patient with Duchenne Muscular Dystrophy
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Induced pluripotent stem cell (iPSC) methods were used to create beating heart cells (cardiomyocytes) starting from the urine of a patient with Duchenne muscular dystrophy (DMD). Urine stem cells (USCs) were transduced with oct4, sox2, c-myc and klf4. Pluripotency of multiple iPSC clones was confi rmed by immunohistochemistry, RT-PCR and teratoma formation (Fig 1) . Fig 1: (A) iPSC colony derived from healthy donor urine cells (USC-iPSC) or human embryonic stem cell (hESC H9) colony. (B) RT-PCR for genes highly expressed in human embryonic stem cells for iPSC clones (n=4) from healthy donor and DMD patient. Relative values (2Ct) were normalized against the GAPDH/ © iPSC colony derived from normal human urine cells probed with antibodies highly expressed on human embryonic stem cells. Scale bar, 200 m; (D) HE staining of teratomas. Scale bar, 100 m. Urine-derived iPSCs were differentiated into beating cardiomyocytes in vitro over about 14 days using a combination of growth factors. To determine if urine-derived cardiomyocytes faithfully retain the donor's genetic information, we created urine-derived cardiomyocytes from a patient with Duchenne muscular dystrophy (DMD), a monogenic disease caused by dystrophin mutation. Urine-derived cardiomyocytes from the DMD patient were probed by immunocytochemistry demonstrating that dystrophin could not be detected wheras urinederived cardiomyocytes generated from healthy donors (n=3) demonstrated dystrophin staining (Fig 2) . While both WT and DMD cardiomyocytes were positive for cardiac specifi c -actinin and cTnI, dystrophin was not detected in DMD cardiomyocytes. Together these results demonstrate the feasibility of generating urine-derived cardiomyocytes that recapitulate characteristic features of the patient's phenotype that can be used for studying disease etiology as well as a drug-screening platform. Therapeutic compounds identifi ed using this approach will have a higher likelihood of working in the patient because the patient's own cells were used and the compound was identifi ed by its ability to correct the phenotypic defect in the dish. Myocardial infarction and heart failure are leading causes of death worldwide. Because the heart has very limited regenerative capacity, endogenous cell regeneration is not suffi cient to repair heart damage. The concept of cell replacement has become an appealing therapy to treat such cardiac diseases. Human embryonic stem cells (hESC) are an attractive source for the cell replacement therapy since they can be greatly expanded in culture and differentiated into specifi c cell lineages under proper inductions. To provide suffi cient hESC-derived cardiomyocytes for pre-clinical and clinical studies, a robust scalable differentiation system for cardiomyocyte production is essential. Previously we have established a scalable hESC suspension culture system with defi ned culture conditions. Using hESCs generated from the suspension culture system, we have developed a scalable differentiation process in adherent format, with which hESCs cultured on Matrigel are induced for cardiac differentiation by sequential treatment of Activin A and BMP4. This process has been applied to large-scale manufacturing of hESC-derived cardiomyocytes with S183 PLURIPOTENT STEM CELLS 50-80% purity. For potential clinical application, we also develop a differentiation process with small molecule induction on cells grown on a defi ned matrix. Under this defi ned system, hESCs can be differentiated to cardiomyocytes with over 80% purity in a large scale vessel. We further use the small molecule induction approach to directly differentiate the hESC suspension culture in spinner fl asks without matrix addition. With this scalable suspension culture system, we are able to obtain over 80% cardiomyocytes after differentiation. The suspension culture system from expansion of undifferentiated hESCs to cardiomyocyte differentiation provides a bioreactor prototype for automation of cell manufacturing. In summary, we have developed robust processes for scalable manufacturing of hESC-derived cardiomyocytes in both adherent and suspension culture systems that will accelerate the advance of pre-clinical and clinical studies. The ability to modulate vasculogenesis and angiogenesis could allow for the development of therapies for numerous physiological and pathological states associated with vessel formation, such as wound healing, tumor growth and ischemic disease. Such techniques can also be applied to the fi eld of regenerative medicine where the development of vascular supply systems is necessary for the functionality of engineered tissues. In order to generate microvascular networks in vitro , a readily available and expandable source of endothelial cells capable of vessel formation is required. The derivation of endothelial cells from embryonic stem cells (ESC) offers a potential source of vascular cells and it has been suggested that bone marrow derived mesenchymal stem cells (MSCs) may function as pericytes and play an important role in regulating vascular morphogenesis. The present study aims to create mouse ESC-derived microvascular networks and investigate the interactions between MSCs and vascular progenitor cells in the context of angiogenesis. Mouse ES-R1 embryonic stem cells were characterized by expression analysis for pluripotency markers Oct4, Sox2, SSEA-2 and Nanog. For endothelial differentiation, mouse R1 ESC were seeded on ECM (either collagen type IV or fi bronectin) for 2-5 days. Two differentiated cell populations were collected for experimentsmixed vascular progenitors (VPC) with no selection and FLK1 VPC isolated by FACS for FLK1/VEGFR2. Both cell populations were characterized by fl ow cytometry analysis for endothelial and smooth muscle cell markers. Next, co-culture experiments were performed to assess the effect of MSCs on angiogenesis-relevant behavior such as migration, proliferation and vessel-like structure formation in Matrigel™. Migratory capacity of both mixed VPC and FLK1 VPC was signifi cantly increased in response to MSCs. Increased cell number and viability was also observed when both VPC populations were co-cultured with MSCs, as well as greater proliferation. In Matrigel™, mixed VPCs alone, FLK1 VPCs alone or MSCs alone did not form networks. However, formation of microvascular-like structures did occur in the presence of MSCs. -both tubule length and number of tubule junctions was signifi cantly increased in both progenitor cell populations. This effect was observed to be both time and dose dependent. Addition of MSCs to mixed VPCs increased network formation when both cell types were present in equal numbers. For FLK1 VPC, MSC addition after time zero in ratios of 1:1 and 2:1 (FLK1 VPC:MSC) resulted in network formation. Further optimization of network stability in terms of MSC dose and time of addition is currently underway. These results suggest that MSCs play an important role in angiogenesis and may enable VPC function, indicative of a pericyte role. Furthermore, terminal endothelial differentiation of ESCs may not be strictly necessary for in vitro microvascular network formation. In conclusion, these data may have potential implications for sourcing of functional vascular cells applicable to tissue engineering and cell therapeutics, warranting further study in the area. Human pluripotent stem cells represent an important source of cellular therapies in regenerative medicine and related research. Center of Biomedicine and Genetics (CBG) has been actively engaged in the large scale cGMP production of human embryonic stem cells (hESC) and stem cells derived cell products, including hESC, hESC-derived retinal pigment epithelium (RPE) cells, hESC-derived neurons, hESC-derived Cardiomyocyte and hESC-derived neural stem cells for clinical study and research purpose. To ensure the safety and effectiveness of the fi nal product there is a need to develop quality control assays to characterize the quality for starting material, in processing sample and fi nal product. Both Flow cytometry and RT-PCR-based assays have been widely used in the characterization of the cellular products. The microbial contamination of initial culture needs to be ruled out before the large scale cGMP production by performing sterility and Mycoplasma testing. For example, CBG developed a real-time quantitative polymerase chain reaction (RT-PCR) assays for Treponema pallidium (Syphilis) detection for the release testing of a Master Cell Bank of neural stem cells. The test is required by FDA for all banks where the original cells were derived from a donor before 25 th May 2005. Other than microbial contamination, the absence of the residual cell from feeder layer needs to be demonstrated. Also, a sensitive RT-PCR method has been developed to detect low level of residual mouse feeder cells from the background of human cells. Besides the infectious agents, the fi nal cell products need to be characterized using Flow cytometric and real-time quantitative polymerase chain reaction (RT-qPCR) assays to detect and quantify the expression of specifi c markers associated with the fi nal product or other contaminating cell types. In addition to traditional RT-pQPCR, single cell RT-qPCR assay is also developed to evaluate the gene expression profi le in individual cells instead of a cell population. We have used a systematic approach for the development and qualifi cation of assays for stem cell products. This approach comprises: 1) selection, qualifi cation and banking of critical reagents; 2) selection and banking of positive control and negative control materials; 3) assessing assay precision and reproducibility ; 4) performing qualifi cation runs; 5) preparation of assay qualifi cation technical reports and standard operating procedures (SOPs). In the poster, we describe how we evaluate assay parameters such as precision, sensitivity, specifi city, and dynamic range (linearity) during assay qualifi cation.
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